<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03404089</url>
  </required_header>
  <id_info>
    <org_study_id>2015_78</org_study_id>
    <secondary_id>2016-A01407-44</secondary_id>
    <secondary_id>HEALTH.2013.2.3.1-2</secondary_id>
    <nct_id>NCT03404089</nct_id>
  </id_info>
  <brief_title>Bedside Therapeutic Monitoring of β-Lactam Levels in Newborns, Children and Adolescents Admitted to Intensive Care.</brief_title>
  <acronym>MON4STRAT</acronym>
  <official_title>Bedside Therapeutic Monitoring of β-Lactam Levels in Newborns, Children and Adolescents Admitted to Intensive Care: Study of a Pharmacokinetics Monitoring Method.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluate the capacity of the MON4STRAT device for drug monitoring of β- lactam&#xD;
      antibiotic concentrations in newborns, children, and adolescents admitted in intensive care&#xD;
      units with a health care-associated infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 18, 2018</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between the β-lactam dosage measured by the MON4STRAT method and the β-lactam dosage measured by the HPLC-MS-MS (the reference method).</measure>
    <time_frame>at 3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>User's questionnaire</measure>
    <time_frame>at 3 days</time_frame>
    <description>The feasibility of the MON4STRAT method will be evaluated by a questionnaire to be completed by the users of the method, that is, the nurses caring for these patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum concentration of beta-lactams antibiotics</measure>
    <time_frame>before antibiotic infusion at day 3 and 2/3 hours after the end of antibiotic infusion</time_frame>
    <description>Pharmacokinetic of beta-lactams antibiotics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (CMax) of beta-lactams antibiotics</measure>
    <time_frame>before antibiotic infusion at day 3 and 2/3 hours after the end of antibiotic infusion</time_frame>
    <description>Pharmacokinetic of beta-lactams antibiotics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (Cl) of beta-lactams antibiotics</measure>
    <time_frame>before antibiotic infusion at day 3 and 2/3 hours after the end of antibiotic infusion</time_frame>
    <description>Pharmacokinetic of beta-lactams antibiotics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution of beta-lactams antibiotics</measure>
    <time_frame>before antibiotic infusion at day 3 and 2/3 hours after the end of antibiotic infusion</time_frame>
    <description>Pharmacokinetic of beta-lactams antibiotics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t1/2) of beta-lactams antibiotics</measure>
    <time_frame>before antibiotic infusion at day 3 and 2/3 hours after the end of antibiotic infusion</time_frame>
    <description>Pharmacokinetic of beta-lactams antibiotics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the course of infection of children who had a β-lactam assay (by the reference method) at the usual levels and those who appeared to receiving inadequate β-lactam doses.</measure>
    <time_frame>at 17 days</time_frame>
    <description>Antimicrobial doses, serum concentration of β- lactams and minimum inhibitory concentration of microorganisms, if available, will be used to assess the potential usefulness of this bedside method</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Intensive Care Unit Syndrome</condition>
  <arm_group>
    <arm_group_label>pharmacokinetic device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MON4STRAT system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>pharmacokinetic device</intervention_name>
    <description>MON4STRAT system: bed-side pharmacokinetic device for drug concentration measurement</description>
    <arm_group_label>pharmacokinetic device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>pharmacokinetic device</intervention_name>
    <description>High performance liquid chromatography, (HPLC), the reference methods HLPC tandem mass spectrometry or Ultraviolet are using</description>
    <arm_group_label>pharmacokinetic device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age younger than 18 years&#xD;
&#xD;
          -  Newborns (preterm or not) in neonatal intensive care&#xD;
&#xD;
          -  Infants, children, and adolescents in pediatric intensive care&#xD;
&#xD;
          -  Clinically suspected or microbiologically proven sepsis that might be associated with&#xD;
             ventilator-associated pneumonia or otherwise associated with health care&#xD;
&#xD;
          -  Need for antibiotic treatment by piperacillin-tazobactam, ceftazidime, or meropenem of&#xD;
             intermittent administration&#xD;
&#xD;
          -  Informed consent form signed by parents/guardian&#xD;
&#xD;
          -  Informed consent form signed by patients old enough to understand.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Process for active limitation of treatment underway&#xD;
&#xD;
          -  Suspected or known hypersensitivity to studied beta-lactams&#xD;
&#xD;
          -  Renal failure, defined as serum creatinine &gt; 1.5 mg/dl or urine production &lt; 0.3 ml/kg&#xD;
             for 24 h or anuria for 12 h.&#xD;
&#xD;
          -  Co-administration of two β-lactam antibiotics&#xD;
&#xD;
          -  Cystic fibrosis&#xD;
&#xD;
          -  No national health insurance coverage in French center&#xD;
&#xD;
          -  Family unable to understand study-related information due to language or other&#xD;
             communication issues&#xD;
&#xD;
          -  No consent obtained&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François DUBOS, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>François DUBOS, MD,PhD</last_name>
    <phone>3 20 44 46 64</phone>
    <phone_ext>+33</phone_ext>
    <email>francois.dubos@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Roger Salengro, CHU</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>françois DUBOS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 28, 2017</study_first_submitted>
  <study_first_submitted_qc>January 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2018</study_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>device drug monitoring</keyword>
  <keyword>β-lactam antibiotic</keyword>
  <keyword>health care-associated infection</keyword>
  <keyword>MON4STRAT</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

